摘要
目的 分析恩替卡韦联合自体骨髓干细胞移植对乙肝肝硬化患者的治疗作用.方法 选择乙肝肝硬化失代偿期患者78例.从患者髂后上棘抽取骨髓,体外分离纯化骨髓源性干细胞,经过股动脉穿刺植入肝脏.在术后2、4、8周复查谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)、白蛋白(ALB)及凝血酶原时间(PT)等相关实验室指标.结果 术后第4周和第8周,大多数患者的临床症状和体征得到明显改善,其中腹水减少或减轻者分别为68例和72例,乏力症状得到改善者分别为69例和75例,腹胀减轻者分别为69例和72例.干细胞移植后第4周,多项实验室指标出现显著变化,ALT、AST、TBIL明显下降,ALB、PT得到明显改善.结论 自体骨髓干细胞(BMSC)肝内移植是临床治疗失代偿期乙肝肝硬化的补充.
Objective Analysis of entecavir combined with autologous bone marrow stem cell transplantation on the treatment of patients with liver cirrhosis.Methods Select decompensated liver cirrhosis 78 patients.From the patient's bone marrow posterior superior iliac spine,Purification of in vitro bone marrow-derived stem cells,Through the femoral artery puncture implanted liver.After surgery in patients 2,4,8 weeks to check the relevant laboratory parameters.Results Our first four weeks after surgery and eight weeks found that most patients with clinical signs and symptoms have markedly improved,Ascites reduce or mitigate the total 68 cases and 72 cases,fatigue symptoms improved with 69 cases and 75 cases,reduce bloating in patients with 69 cases and 72 cases.We found that in the first four weeks after surgery,a number of indicators have been significant changes,ALT,AST,TBIL decreased,ALB,PT％ improved significantly.Conclusion BMSC transplantation in liver itself is a significant advancement of clinical treatment and beneficial supplement BMSC liver transplantation to patients a new choice.
出处
《中国临床实用医学》
2014年第1期-,共3页
China Clinical Practical Medicine
基金
国家十一五科技重大专项资金资助项目
